CareDx, Inc. (CDNA) Stock
Key stats
- Market cap
- $4.26B
- Price / Earnings ratio
- 33.0x
- EPS (TTM)
- $2.49
- Volume
- Loading
- 52-week high
- $90.87
- 52-week low
- $15.15
Source: third-party data provider, as of November 13, 2026
Compare with CDNA
Recent news
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
CDNA
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CDNA
CareDx Announces Third KOAR Analysis Published in Transplantation
CareDx Announces Third KOAR Analysis Published in Transplantation
CDNA
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
CDNANews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 59.65
- MACD 12/26/9
- 5.22
- EMA 9 of MACD
- 5.31
- MACD histogram
- -0.08
- SMA 50
- $65.18
- Price above SMA 50
- EMA 50
- $66.71
- Price above EMA 50
- SMA 200
- $36.13
- Price above SMA 200
- EMA 200
- $41.16
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.03 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
CDNACareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CDNACareDx Announces Third KOAR Analysis Published in Transplantation
CareDx Announces Third KOAR Analysis Published in Transplantation
CDNACathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
CDNA
Why CareDx Stock Soared Today
Why CareDx Stock Soared Today
CDNA
What CareDx (CDNA) Said on Its Q3 Earnings Call
What CareDx (CDNA) Said on Its Q3 Earnings Call
CDNA
CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates
CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates
CDNA
CareDx Announces Third Quarter 2026 Financial Results
CareDx Announces Third Quarter 2026 Financial Results
CDNA
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
CDNA
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
CDNANews tone: automated (AI) classification of the article's content, not a price prediction.
About CareDx, Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. John Walter Hanna Jr. | President, CEO & Director | 1980 |
| Mr. Keith S. Kennedy C.F.A., CPA | CFO & COO | 1970 |
| Mr. Jeffrey A. Novack | General Counsel & Secretary | 1984 |
| Ms. Jessica Meng | Chief Commercial Officer | 1975 |
| Mr. Kashif Rathore | Chief Technology Officer | — |
| Dr. Robert N. Woodward Ph.D. | Chief Scientific Officer | — |
| Ms. Nina D. Deka | Head of Investor Relations | — |
| Ms. Natasha Moshirian Wagner | Vice President of Corporate Communications | — |
| Ms. Marica Grskovic Ph.D. | Chief Strategy Officer | — |
| Ms. Jing Huang Ph.D. | Chief Data & Artificial Intelligence Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 59.65
- MACD 12/26/9
- 5.22
- EMA 9 of MACD
- 5.31
- MACD histogram
- -0.08
- SMA 50
- $65.18
- Price above SMA 50
- EMA 50
- $66.71
- Price above EMA 50
- SMA 200
- $36.13
- Price above SMA 200
- EMA 200
- $41.16
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $80.00
- Average
- $90.67
- High
- $100.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -8.2 | +8.3 | ||||||||||
| 2022 | -10.3 | -8.7 | -2.9 | -21.9 | -22.8 | -15.5 | +6.2 | -16.0 | -16.2 | +14.1 | -35.4 | -13.4 |
| 2023 | +34.6 | +7.4 | -42.9 | -7.4 | -3.9 | +6.1 | +28.5 | -11.2 | -28.1 | -21.1 | +79.5 | +21.5 |
| 2024 | -28.3 | +19.8 | -11.8 | -24.8 | +41.7 | +16.2 | +30.0 | +30.3 | +6.2 | -28.5 | +8.4 | -16.5 |
| 2025 | +8.3 | -5.0 | -16.0 | -4.6 | +12.7 | +14.4 | -34.8 | +11.8 | +5.0 | +0.0 | +21.0 | +9.7 |
| 2026 | +7.4 | -8.1 | -7.4 | +16.5 | +6.1 | +25.0 | +49.4 | +4.7 | +32.7 | +32.0 | -5.5 |
